Member Info for BurtonD

the one purpose for empire metals is to get the pitfield titanium giant into final product.

“…we’re almost there. we’re on the cusp of this breakthrough…”

full feature link : **********************************/2025/02/empire-metals-ltd-feb-2025/

video link only : https://youtu.be/gvkhxbvhkiu

I guess the key is the Cameroon license extension. Get that done and everything else fits into place as I understand it.

“…Completion of the farm-out transaction is expected by the end of Q1 2025 given that approvals from the Government of the Republic of Cameroon will be required…”

Following the success of our pilot human metapneumovirus (hMPV) characterisation trial, we have signed a contract with a new biopharmaceutical client to complete the final stage of the characterisation study ahead of future hMPV human challenge trials.

💡 Pilot characterisation trial validated the viability of hVIVO’s hMPV human challenge model

Next phase aims to expand the dataset, further strengthening the model

Expected to commence H1 2025

Subject to successful completion of this study & necessary regulatory approvals, we should be in a position to commence hMPV human challenge trials from H225

https://www.londonstockexchange.com/news-article/HVO/ps2m-hmpv-characterisation-study-contract/16901311

a new article from @tmsreach

“…the company has established a solid reputation as a gold-focused exploration firm. however, what many may not be aware of is that the company also owns an exciting lithium asset…”

**********************************/2025/02/first-class-metals-plc/

Burton knows what? Think about the exit route for ECR BOD. Its not rocket science!

Https://www.thetimes.com/business-money/entrepreneurs/article/boardroom-stars-2025-non-executive-director-awards-9vgk7kxn0

Https://www.thetimes.com/business-money/entrepreneurs/article/boardroom-stars-2025-non-executive-director-awards-9vgk7kxn0

Https://www.thetimes.com/business-money/entrepreneurs/article/boardroom-stars-2025-non-executive-director-awards-9vgk7kxn0

the tms team catch up with altona rare earths and discus fluorspar, the financials, what is next for the company and what is the overall strategy.

**********************************/2025/02/a-question-and-answer-session-with-altona-rare-earths-plc/

 

“…why would a huge company like @harmonygoldnews want to have to deal with a junior explorer like #lex…”

**********************************/2025/02/lexington-gold-ltd-11/

Https://www.europeangreentransition.com/investors/reports-presentations/

#LEX recently acquired White Rivers exploration (WRE) a Globally significant Gold portfolio in Witwatersrand Goldfields.

WRE has an incorporated JV arrangement with Avgold Ltd, a subsidiary of Harmony Gold

https://www.miningmx.com/trending/59811-harmony-gold-on-track-to-beat-production-forecast-for-2025/

Shionogi published positive results from a human challenge trial, conducted by #HVO, for its RSV antiviral candidate.

These results demonstrate the significant role that human challenge trials can play in the drug development space, by generating rapid efficacy data and reducing risk in later-stage trials.

This is important for viruses such as RSV, that severely impacts vulnerable patients such as infants, the elderly and immunocompromised individuals.

With hVIVO's decades of expertise in human challenge trials, the team can leverage this knowledge to accelerate the delivery of promising new treatments to patients. 

Shionogi, a leading global research-driven pharmaceutical company headquartered in Osaka, Japan, also released their own press release on the positive news here :

https://www.shionogi.com/content/dam/shionogi/seu/news/pdf/2025/_NP-EU-S-337395%20Shionogi%20announces%20results%20from%20RSV%20human%20challenge%20trial-%20primary%20endpoint%20reached.pdf

Https://issuu.com/intinvestor/docs/iimag-issue-winter-2025

Https://www.empiremetals.com/wp-content/uploads/2025/02/Empire-Metals_Corporate-Presentation_2025-02-02.pdf

**********************************/2025/02/the-challenges-and-opportunities-for-uk-markets-in-2025/

big feature on egt from @tmsreach

**********************************/2025/02/the-challenges-and-opportunities-for-uk-markets-in-2025/

…lots to like.

https://www.youtube.com/watch?v=uryvUzvHKkk

Https://www.londonstockexchange.com/news-article/HVO/rsv-contract-signed-with-inhalon-biopharma/16880482

hVIVO is delighted to add yet another company to its list of clients - Inhalon Biopharma.

The Company has signed a human challenge trial contract which will assess Inhalon’s inhaled (mucosal) IN-002 antiviral candidate using hVIVO’s world renowned RSV Human Challenge Model. The study will take place at their state-of-the-art facility in Canary Wharf in H2 2026, with the majority of revenue expected to be recognised in 2026.

hVIVO previously identified the next generation of vaccines and antivirals to include mucosal based delivery systems and had targeted this as a being a key growth drive for their challenge trial business going forward.

They are delighted to have received such an exciting project, particularly with a new client. The company has now seen a number of contracts coming across the line recently and the orderbook for 2026 growing with this latest contract.

Warrants sellers out out!!